Table 1.
Demographic and baseline characteristics of patients in the training and validation cohorts.
| Characteristics | Training cohort (N = 6416) | Validation cohort (N = 627) |
|---|---|---|
| Age, years | ||
| <45 | 3116 (48.6) | 203 (32.3) |
| ≥45 | 3300 (51.4) | 424 (67.7) |
| Gender | ||
| Male | 4753 (74.1) | 446 (71.1) |
| Female | 1663 (25.9) | 181 (28.9) |
| Smoking | ||
| No | 4107 (64.0) | 520 (82.9) |
| Yes | 2309 (36.0) | 107 (17.1) |
| Alcohol | ||
| No | 5510 (85.9) | 549 (87.6) |
| Yes | 906 (14.1) | 78 (12.4) |
| Family history | ||
| No | 4706 (73.3) | 603 (96.2) |
| Yes | 1710 (26.57) | 24 (3.8) |
| Histological type | ||
| WHO Type I | 36 (0.6) | 25 (4) |
| WHO Type IIa/IIb | 6380 (99.4) | 602 (96) |
| T categorya | ||
| T1 | 667 (10.4) | 96 (15.3) |
| T2 | 1141 (17.8) | 146 (23.3) |
| T3 | 3048 (47.5) | 141 (22.5) |
| T4 | 1560 (24.3) | 244 (38.9) |
| N categorya | ||
| N0 | 820 (12.8) | 43 (6.9) |
| N1 | 2965 (46.2) | 326 (52.0) |
| N2 | 1973 (30.8) | 170 (27.1) |
| N3 | 658 (10.3) | 88 (14.0) |
| EBV DNA | ||
| ≤2000 copies/mL | 2971 (46.3) | 468 (74.6) |
| >2000 copies/mL | 3445 (53.7) | 159 (25.4) |
| Groupingsb | ||
| I | 367 (5.7) | 22 (3.5) |
| II | 3472 (54.1) | 300 (47.8) |
| III | 1863 (29.0) | 217 (34.6) |
| IV | 714 (11.1) | 88 (14.0) |
| Chemotherapy | ||
| CRT | 5678 (88.5) | 589 (93.9) |
| RT alone | 738 (11.5) | 38 (6.1) |
| HGB | ||
| ≤130 g/L | 1180 (18.4) | 270 (43.1) |
| >130 g/L | 5236 (81.6) | 357(56.9) |
| ALB | ||
| ≤40 g/L | 609 (9.5) | 161 (25.7) |
| >40 g/L | 5807 (90.5) | 466 (74.3) |
| CRP | NA | |
| ≤3 mg/L | 6515 (69.7) | |
| >3 mg/L | 2833 (30.3) | |
| LDH | NA | |
| ≤245 IU/L | 5,891 (91.8) | |
| >245 IU/L | 515 (8.2) | |
WHO, World Health Organization; EBV, Epstein–Barr virus; HGB, hemoglobin; ALB, albumin; CRP, C-reactive protein; LDH, lactate dehydrogenase; CRT, chemoradiotherapy; RT, radiotherapy; IU, international unit (s).
aAccording to the American Joint Committee on Cancer, 8th edition.
bPatients were grouped according to T category, N category and EBV DNA.